VER Vernalis

TIDMVER

RNS Number : 6343J

Vernalis PLC

30 June 2017

TOTAL VOTING RIGHTS

VERNALIS PLC (the "Company")

30 June 2017

Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,445,230 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company is therefore 526,445,230.

The above figure of 526,445,230 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company.

- ends -

Enquiries:

 
 Vernalis plc:                              +44 (0) 118 938 0015 
 Ian Garland, Chief Executive Officer 
  David Mackney, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated 
  Adviser):                                 +44 (0) 20 7523 8000 
 Henry Fitzgerald-O'Connor 
  Emma Gabriel 
 Shore Capital (Joint Broker):              +44 (0) 20 7408 4090 
 Bidhi Bhoma 
  Toby Gibbs 
 FTI Consulting:                            +44 (0) 20 3727 1000 
 Ben Atwell 
  Simon Conway 
  Stephanie Cuthbert 
 

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra(R) XR targeting the US prescription cough-cold market; Moxatag(R) , a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focused on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRUKVSRBSANUAR

(END) Dow Jones Newswires

June 30, 2017 02:00 ET (06:00 GMT)

Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2024 to May 2024

Vernalis (LSE:VER)
Historical Stock Chart
From May 2023 to May 2024